ABRYSVO™
Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine

RSVpreF is part of the new NACI recommendations on the prevention of RSV disease in older adults[3]

## Help protect against RSV-LRTD

# Start with ABRYSVO™

ABRYSVO (respiratory syncytial virus stabilized prefusion F subunit vaccine) is a bivalent vaccine indicated for:[1]

- Active immunization of pregnant individuals from 32 through 36 weeks' gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.
- The prevention of LRTD caused by RSV in individuals 60 years of age and older by active immunization.

> The **only** vaccine indicated in both RSV-caused LRTD in individuals ≥ 60 years of age **and** RSV-caused LRTD/severe LRTD in infants from birth to 6 months of age[2]*

RSV: respiratory syncytial virus; LRTD: lower respiratory tract disease; NACI: National Advisory Committee on Immunization

*Comparative clinical significance has not been established.

## CERTAIN CHRONIC CONDITIONS INCREASE THE RISK FOR SEVERE RSV DISEASE[4]

- Cardiac or pulmonary disorders (COPD, asthma, etc.)
- Diabetes and other metabolic diseases
- Moderate and severe immunodeficiency
- Chronic renal disease
- Chronic liver disease
- Neurologic or neurodevelopmental conditions
- Obesity (BMI ≥ 40 kg/m$^2$)

## DEMONSTRATED POWERFUL PREVENTION AGAINST RSV-LRTD[1*†]

**Statistically significant relative risk reduction of first episode of RSV-LRTD vs. placebo**

**85.7%**
**reduction in the risk of first episode of RSV-LRTD with ≥ 3 symptoms**

(96.66%; CI: 32.0, 98.7)

(Case counts: ABRYSVO n=2/16,306; placebo n=14/16,308‡)

**66.7%**
**reduction in the risk of first episode of RSV-LRTD with ≥ 2 symptoms**

(96.66%; CI: 28.8, 85.8)

(Case counts: ABRYSVO n=11/16,306; placebo n=33/16,308‡)

Adapted from the ABRYSVO Product Monograph.[2]

## ABRYSVO CAN BE ADMINISTERED IN 3 STEPS[1]

Adjuvant-free, **bivalent** vaccine[1,5§]

### Step 1:

Attach vial adapter



### Step 2:

Reconstitute to form ABRYSVO



### Step 3:

Withdraw to inject

For complete dosing and administration information, please consult the Product Monograph.

§Comparative clinical significance has not been established.

COPD: chronic obstructive pulmonary disease;
BMI: body mass index

## DEMONSTRATED EXCELLENT SAFETY PROFILE[1]

In the RENOIR trial, the most frequently reported adverse reaction was **vaccination site pain (10.5%)**.[¶]

The majority of reactions were mild to moderate in severity and resolved within **1–2 days** of onset.

CI: confidence interval

RT-PCR: reverse transcription-polymerase chain reaction

*The statistical criterion for success was defined as a CI lower bound > 20%.
†RSV-associated LRTD was defined as RT-PCR confirmed RSV illness with ≥ 2, or ≥ 3, of the following respiratory symptoms within 7 days of symptom onset and lasting more than 1 day during the same illness – new or increased cough, wheezing, sputum production, shortness of breath, or tachypnea (≥ 25 breaths/min or 15% increase from resting baseline).
‡Evaluable efficacy population.




**Learn more about ABRYSVO**

¶RENOIR: A Phase 3, multicentre, randomized, double-blind, placebo-controlled global study comparing ABRYSVO (n=16,306) to placebo (n=16,308) in individuals ≥ 60 years receiving one dose (0.5 mL) of ABRYSVO (120 mcg [60 mcg each of subgroup A and B, without an adjuvant (i.e. $AlOH_3$)]) or placebo intramuscularly. The primary objective was assessment of vaccine efficacy, defined as the relative risk reduction of the first episode of RSV-associated lower respiratory tract infection starting 14 days after study vaccination in the ABRYSVO group compared to the placebo group in the first RSV season. The statistical criterion for success was defined as a CI lower bound > 20%.

## RSVpreF IS INCLUDED AS AN OPTION IN THE NACI STATEMENT ON THE PREVENTION OF RSV DISEASE IN OLDER ADULTS[3]

**NACI recommends:**

1. RSV immunization programs for **adults 75 years of age and older**, particularly for older adults at increased risk of severe RSV disease.
2. RSV immunization programs for **adults 60 years of age and older** who are **residents of nursing homes and other chronic care facilities**.
3. That immunization with an RSV vaccine may be considered as an individual decision by **adults 60 to 74 years of age** with their health care provider.

Listed in the NACI guidelines

**See the complete statement**

## SAFETY INFORMATION[1]

**Clinical use:**
Safety and efficacy have not been established in pediatrics (< 18 years of age). Limited data are available in pregnant adolescents and their infants.

**Contraindications:**
- Patients with a known hypersensitivity to the active substance or to any component of the vaccine

**Relevant warnings and precautions:**
- Medical treatment should be available in case of a rare anaphylactic event following the administration of ABRYSVO
- Syncope (fainting) may occur with administration of injectable vaccines
- As with any vaccine, ABRYSVO will not protect 100% of those who receive it
- Postpone in those with acute febrile illness
- As with other vaccines administered intramuscularly, use with caution in those with thrombocytopenia or a coagulation disorder
- Immunocompromised individuals may have diminished response to ABRYSVO

**For more information:**
Consult the Product Monograph at https://www.pfi.sr/abrysvo-pm for important information relating to adverse reactions, drug interactions, and dosing that has not been discussed in this piece. The Product Monograph is also available by calling 1-800-463-6001.

### Provincial and federal funding are now available in select provinces.

Restrictions may apply. Refer to your respective provincial and federal listings for full coverage details and restrictions.[6]*
The cost of ABRYSVO may be covered by your patient's private insurance. They can contact their insurance provider to find out.

*Funding is available in Ontario, Quebec, Alberta, Manitoba, New Brunswick, Nova Scotia, Yukon, and covered on Veterans Affairs Canada as of November 2024.

**References: 1.** ABRYSVO Product Monograph. Pfizer Canada ULC. May 29, 2024. **2.** Data on file. Pfizer Canada ULC. December 22, 2023. **3.** Statement on the prevention of respiratory syncytial virus (RSV) disease in older adults. National Advisory Committee on Immunization (NACI). July 2024. **4.** Government of Canada. Respiratory syncytial virus (RSV) vaccines: Canadian Immunization Guide. Accessed August 13, 2024. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html#a2.2. **5.** Data on file. Pfizer Canada ULC. February 26, 2024. **6.** Data on file. Pfizer Canada ULC. November 11, 2024.

ABRYSVO™
Pfizer Canada ULC
© 2024 Pfizer Canada ULC
Kirkland, Quebec H9J 2M5

PP-A1G-CAN-0100

MEMBER OF INNOVATIVE MEDICINES CANADA

REVIEWED BY PAAB